Table 4.

Contingency analysis during anti-TNF induction therapy

	IFX					ADA
	Cutoff	OR + 95% CI	P	Sensitivity	Specificity	Cutoff value	OR + 95% CI	P	Sensitivity	Specificity
C3M wk 6 (IFX), wk 8 (ADA)	13.99 nmol/L	14.00 (1.38–190.60)	0.05	0.93	0.50	14.13 nmol/L	14.67 (1.17–191.10)	0.04	0.92	0.57
C3M/PRO-C3 wk 2	1.3 nmol/L	Infinity (2.974-Infinity)	0.02	0.94	1.00
C3M/PRO-C3 wk 8						1.1 nmol/L	21.00 (1.80–284.10)	0.03	0.88	0.75
PRO-C4 wk 1						334.52 nmol/L	7.50 (0.88–96.42)	0.15
C4M wk 6 (IFX), wk 8 (ADA)	25.58 nmol/L	9.75 (1.04–133.80)	0.09			33.96 nmol/L	52.00 (2.31–656.50)	0.01	0.93	0.80
PRO-C4 wk 6 (IFX), wk 8 (ADA)	381.63 nmol/L	16.00 (1.14–240.30)	0.08			385.22 nmol/L	19.50 (1.67–265.10)	0.04	0.87	0.75

ADA, adalimumab; CI, confidence interval; IFX, infliximab; OR, odds ratio.